NCT03543826View on ClinicalTrials.gov

Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex

PHASE4CompletedINTERVENTIONAL

Enrollment

201

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

November 26, 2018

Study Completion Date

November 26, 2018

Conditions

Muscle Weakness

Interventions

COMBINATION_PRODUCT

Protocol for rocuronium neuromuscular block

The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.

Trial Locations (1)

98195

University of Washington Medical Center, Seattle

All Listed Sponsors

lead

University of Washington

OTHER

NCT03543826 - Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex | Biotech Hunter | Biotech Hunter